LIFECORE BIOMEDICAL, INC. DE
LFCR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LFCR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LFCR
LIFECORE BIOMEDICAL, INC. DE (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that provides high-quality pharmaceutical manufacturing services, including aseptic filling and related capabilities.
Key risk: High debt and negative equity
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
LIFECORE BIOMEDICAL, INC. DE (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that provides high-quality pharmaceutical manufacturing services, including aseptic filling and related capabilities.
- Lifecore is a fully integrated CDMO offering high-quality pharmaceutical manufacturing services [sec_mda · as of 2025-08-07].
- In January 2026, Lifecore implemented a new ERP system to enhance inventory control, data visibility, and financial management [sec_mda · as of 2026-08-05].
- The company raised $24.3 million in a private placement of common stock in October 2024 and extended its asset-based lending revolving credit facility with BMO in November 2024 [sec_mda · as of 2026-08-05].
- As of 2026-06-30, Lifecore reported cash & equivalents of $17.2M, total revenue of $34.2M, net income of -$6.2M, shareholders' equity of -$14.2M, and total debt of $156.0M [sec].
- The company has a multi-purpose 5-head aseptic isolator filler, which is a key asset for its manufacturing operations [sec_mda · as of 2026-08-05].
What works
- Lifecore has strengthened its financial position through a $24.3 million private placement in October 2024 and a three-year term extension of its credit facility in November 2024 [sec_mda · as of 2026-08-05].
- The company implemented a new ERP system in January 2026 to improve inventory control, data visibility, and financial management, indicating a focus on operational efficiency [sec_mda · as of 2026-08-05].
- Lifecore possesses a multi-purpose 5-head aseptic isolator filler, a specialized asset that supports its CDMO service offerings [sec_mda · as of 2026-08-05].
What to weigh
- As of 2026-06-30, Lifecore had negative shareholders' equity of -$14.2M and total debt of $156.0M, indicating a highly leveraged balance sheet [sec].
- The company reported a net loss of -$6.2M for the period ending 2026-06-30, reflecting ongoing unprofitability [sec].
- Lifecore faces risks related to its ability to maintain or expand customer relationships and the impact of changes in consumer demand for products it manufactures [sec_mda · as of 2026-08-05].
- The company's future capital requirements depend on numerous factors, including the need for additional financing, which introduces uncertainty [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
Lifecore is a fully integrated CDMO.
“Lifecore is a fully integrated CDMO that offers hi”
SEC MD&A · August 7, 2025
Lifecore implemented a new ERP system in January 2026.
“In January 2026, Lifecore implemented a new enterprise resource planning ("ERP") system designed to enhance inventory control, data visibility, and financial management.”
SEC MD&A · August 5, 2026
Lifecore raised $24.3 million in a private placement in October 2024.
“raising $24.3 million in a private placement of Lifecore common stock in October 2024”
SEC MD&A · August 5, 2026
Lifecore has a multi-purpose 5-head aseptic isolator filler.
“‑speed, multi‑purpose 5‑head aseptic isolator filler.”
SEC MD&A · August 5, 2026
Risks & what to watch (4)›
Key risks
- High debt and negative equity — As of 2026-06-30, total debt was $156.0M and shareholders' equity was -$14.2M, indicating significant leverage [sec].
- Continued net losses — Net income was -$6.2M for the period ending 2026-06-30, reflecting ongoing unprofitability [sec].
- Customer concentration risk — The company's success depends on maintaining relationships with current customers and demand for products it manufactures [sec_mda · as of 2026-08-05].
- Need for additional financing — Future capital requirements depend on numerous factors, including the need for additional financing [sec_mda · as of 2026-08-05].
What to watch
- Ability to generate positive net income and improve shareholders' equity [sec].
- Progress in reducing total debt and improving the balance sheet [sec].
- Customer retention and new business development efforts [sec_mda · as of 2026-08-05].
- Operational improvements from the new ERP system and other initiatives [sec_mda · as of 2026-08-05].
Sources: SEC filings · SEC MD&A · Generated August 10, 2026 · How we verify sources →
Run LIFECORE BIOMEDICAL, INC. DE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LIFECORE BIOMEDICAL, INC. DE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
50.9 months
OCF -$2M · Net income -$6M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
104
Total value held
$82.7M
| Holder | Shares | Value |
|---|---|---|
| 22nw, lp | 1,254 | $18.9M |
| greenhaven road investment management, l.p. | 3,537,573 | $13.2M |
| vanguard capital management llc | 2,580,272 | $9.6M |
| 325 capital llc | 2,162,466 | $8.0M |
| blackrock, inc. | 1,877,305 | $7.0M |
| grizzlyrock capital, llc | 827,488 | $3.1M |
| geode capital management, llc | 815,107 | $3.0M |
| morgan stanley | 764,734 | $2.8M |
| state street corp | 642,006 | $2.4M |
| quinn opportunity partners llc | 453,495 | $1.7M |
Showing top 10 of 104 institutional holders of LIFECORE BIOMEDICAL, INC. DE. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 12.4%
- Days to cover
- 4.3
- Shares short
- 2,651,650
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LFCR short interestGovernance
Frequently asked questions
What is the AI investment thesis for LIFECORE BIOMEDICAL, INC. DE?
LIFECORE BIOMEDICAL, INC. DE (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that provides high-quality pharmaceutical manufacturing services, including aseptic filling and related capabilities.
Who is the CEO of LIFECORE BIOMEDICAL, INC. DE?
Mr. Paul Josephs is the chief executive officer of LIFECORE BIOMEDICAL, INC. DE (LFCR).
Where is LIFECORE BIOMEDICAL, INC. DE headquartered?
LIFECORE BIOMEDICAL, INC. DE (LFCR) is headquartered in Chaska, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.